ResMed (RMD) PT Lowered to $255 at Mizuho

April 13, 2026 6:50 AM

Mizuho analyst Anthony Petrone lowered the price target on ResMed (NYSE: RMD) to $255.00 (from $300.00) while maintaining a Outperform rating.

No results found